{
    "name": "atovaquone/proguanil",
    "comment": "Rx",
    "other_names": [
        "Malarone"
    ],
    "classes": [
        "Antimalarials"
    ],
    "source": "https://reference.medscape.com/drug/malarone-atovaquone-proguanil-342697",
    "pregnancy": {
        "common": [
            "Pregnancy category: C",
            "Lactation: Proguanil is excreted into milk in small quantities, but excretion of atovaquone is unknown; use with caution"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Proguanil is excreted into milk in small quantities, but excretion of atovaquone is unknown; use with caution"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Prophylaxis in severe renal impairment (CrCl <30 mL/min)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Administration does not provide radical cure, nor does it prevent delayed primary attacks of P vivax and P ovale",
                "Patients with severe malaria are not candidates for oral therapy; not evaluated in treatment of cerebral malaria or severe manifestations of malaria (eg, hyperparasitemia, pulmonary edema, renal failure)",
                "Hepatitis and increased transaminase levels reported with prophylactic use; monitor closely; use caution with existing hepatic impairment; hepatic enzyme elevations may persist for four weeks after treatment has ended",
                "Not for treatment of cerebral malaria or other severe manifestations of complicated malaria",
                "Absorption may be reduced in patients with diarrhea or vomiting; monitor closely, and consider antiemetic use; if severe, use alternative antimalarial",
                "Monotherapy may result in parasite relapse of P vivax malaria",
                "Recrudescent P falciparum infection or chemoprophylactic failure after monotherapy should be treated with different schizonticide",
                "Prophylaxis should not be prematurely discontinued; delayed cases of P. falciparum malaria may occur",
                "Complete prophylaxis includes therapy, protective clothing, insect repellents, and bednets",
                "No chemoprophylactic regimen is 100% effective; patient should seek medical care for any febrile illness that occurs",
                "Treatment failure reported in patients >100 kg; monitoring and follow up recommended in this patient group",
                "P falciparum malaria carries higher risk of death and serious complications in pregnant women; patient should discuss risks and benefits of travel, and if travel cannot be avoided, additional prophylaxis, including protective clothing, must be employed"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "dapsone topical",
            "description": {
                "common": "proguanil, dapsone topical. unspecified interaction mechanism. Avoid or Use Alternate Drug. Avoid coadministration of dapsone topical with oral dapsone or antimalarial medications because of the potential for hemolytic reactions."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz decreases levels of atovaquone by unspecified interaction mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bupivacaine implant",
            "description": {
                "common": "atovaquone, bupivacaine implant.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz decreases levels of proguanil by unspecified interaction mechanism. Use Caution/Monitor. May decrease serum concentrations of the active metabolite of proguanil."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir will decrease the level or effect of atovaquone by  unknown mechanism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "metoclopramide intranasal will increase the level or effect of atovaquone by  Other (see comment). Use Caution/Monitor. Metoclopramide may decrease the absorption of atovaquone. Monitor for reduced therapeutic effect of atovaquone."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide decreases levels of atovaquone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tetracycline",
            "description": {
                "common": "tetracycline decreases levels of atovaquone by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Effect may be minor, due to pharmacodynamic synergism."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Abdominal pain",
            "percent": "3-31"
        },
        {
            "name": "Transaminase increases",
            "percent": "17-27"
        },
        {
            "name": "Headache",
            "percent": "3-14"
        },
        {
            "name": "Vomiting",
            "percent": "1-13"
        },
        {
            "name": "Nausea",
            "percent": "12"
        },
        {
            "name": "Asthenia",
            "percent": "8"
        },
        {
            "name": "Diarrhea",
            "percent": "1-8"
        },
        {
            "name": "Pruritus",
            "percent": "6"
        },
        {
            "name": "Anorexia",
            "percent": "5"
        },
        {
            "name": "Dizziness",
            "percent": "5"
        },
        {
            "name": "Dyspepsia",
            "percent": "1-4"
        },
        {
            "name": "Gastritis",
            "percent": "0-3"
        },
        {
            "name": "Fever",
            "percent": null
        },
        {
            "name": "Cough",
            "percent": null
        },
        {
            "name": "Hematologic",
            "percent": null
        },
        {
            "name": "lymphatic",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "anemia",
            "percent": null
        },
        {
            "name": "rarely",
            "percent": null
        },
        {
            "name": "pancytopenia",
            "percent": null
        },
        {
            "name": "patients with severe renal impairment treated with proguanil",
            "percent": null
        },
        {
            "name": "Immunologic",
            "percent": null
        },
        {
            "name": "Allergic reactions",
            "percent": null
        },
        {
            "name": "including angioedema",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "and rare cases of anaphylaxis and vasculitis",
            "percent": null
        },
        {
            "name": "Neurologic",
            "percent": null
        },
        {
            "name": "Rare cases of seizures and psychotic events",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "hallucinations",
            "percent": null
        },
        {
            "name": "GI",
            "percent": null
        },
        {
            "name": "Stomatitis",
            "percent": null
        },
        {
            "name": "Hepatic",
            "percent": null
        },
        {
            "name": "Elevated liver function tests",
            "percent": null
        },
        {
            "name": "LFTs",
            "percent": null
        },
        {
            "name": "rare cases of hepatitis",
            "percent": null
        },
        {
            "name": "cholestasis",
            "percent": null
        },
        {
            "name": "Skin",
            "percent": null
        },
        {
            "name": "Photosensitivity",
            "percent": null
        },
        {
            "name": "rash",
            "percent": null
        },
        {
            "name": "and rare cases of erythema multiforme and Stevens",
            "percent": null
        },
        {
            "name": "Johnson syndrome",
            "percent": null
        }
    ]
}